Inventor · disambiguated record
Christopher J. Kirk
Also filed as: KIRK CHRISTOPHER J · KIRK CHRISTOPHER JUSTIN
8 granted patents·21 pending applications·25 citations·filing 2002–2022
82Inventor score
Top patents by PatentIndex Score
29 records- 0193US9511109B2Combination therapy with peptide epoxyketonesONYX THERAPEUTICS INC·Filed 2014·Granted Dec 6, 2016·10 cites·5 claims
- 0285US8853147B2Use of peptide epoxyketones for metastasis suppressionKIRK CHRISTOPHER J·Filed 2010·Granted Oct 7, 2014·9 cites·20 claims
- 0371US10022326B2Liposomal compositions of epoxyketone-based proteasome inhibitorsONYX THERAPEUTICS INC·Filed 2013·Granted Jul 17, 2018·4 cites·26 claims
- 0468US2020254051A1Combination therapy with peptide epoxyketonesONYX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 0567US9295708B2Modified release formulations for oprozomibONYX THERAPEUTICS INC·Filed 2013·Granted Mar 29, 2016·2 cites·6 claims
- 0667US2023235406A1Immunoglobulin expression levels as biomarker for proteasome inhibitor responseONYX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0767US2011236428A1Combination therapy with peptide epoxyketonesONYX THERAPEUTICS INC·Filed 2009·Application pending·0 cites
- 0865US12076363B2Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancersONYX PHARMA INC·Filed 2021·Granted Sep 3, 2024·0 cites·16 claims
- 0962USRE47954ECombination therapy with peptide epoxyketonesONYX THERAPEUTICS INC·Filed 2017·Granted Apr 21, 2020·0 cites·17 claims
- 1062US2020289606A1Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancersONYX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1161US10596222B2Combination therapy with peptide epoxyketonesONYX THERAPEUTICS INC·Filed 2016·Granted Mar 24, 2020·0 cites·6 claims
- 1260US2021238691A1Immunoglobulin expression levels as biomarker for proteasome inhibitor responseONYX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1358US2020354793A1Immunoglobulin Expression Levels as Biomarker for Proteasome Inhibitor ResponseAMGEN INC·Filed 2020·Application pending·0 cites
- 1454US2003121066A1Transgenic mice containing SOCS-5 cytokine signalling suppressor gene disruptionsFiled 2002·Application pending·0 cites
- 1552US10870889B2Immunoglobulin expression levels as biomarker for proteasome inhibitor responseONYX THERAPEUTICS INC·Filed 2014·Granted Dec 22, 2020·0 cites·13 claims
- 1652US2014364377A1Use of peptide epoxyketones for metastasis suppressionONYX THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 1752US2006193844A1Methods for enzyme inhibitionPROTEOLIX INC·Filed 2006·Application pending·0 cites
- 1851US2016166632A1Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancersONYX THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 1950US2019224270A1Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancersONYX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2049US2006185028A1Transgenic mice containing SOCS-5 cytokine signalling suppressor gene disruptionsALLEN KEITH D·Filed 2006·Application pending·0 cites
- 2147US2006156425A1GNG4 gene disruptions, compositions and methods related theretoALLEN KEITH D·Filed 2005·Application pending·0 cites
- 2244US2003167498A1GNG4 gene disruptions, compositions and methods related theretoFiled 2002·Application pending·0 cites
- 2343US2003140361A1CCR6 chemokine receptor disruptions, compositions and methods relating theretoFiled 2002·Application pending·0 cites
- 2442US2003192069A1Glycerol kinase gene disruptions, compositions and methods related theretoFiled 2002·Application pending·0 cites
- 2538US2006272041A1Cathepsin G (CTSG) Disruptions, Compositions and Methods Relating TheretoWISOTZKEY ROBERT G·Filed 2006·Application pending·0 cites
- 2638US2006248607A1CCR6 chemokine receptor disruptions, compositions and methods relating theretoBRENNAN THOMAS J·Filed 2006·Application pending·0 cites
- 2737US2016213610A1Modified release formulations for oprozomibONYX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2833US2003154503A1Cathepsin G (CTSG) disruptions, compositions and methods relating theretoFiled 2002·Application pending·0 cites
- 2931US2003159168A1CTSZ disruptions, compositions and methods relating theretoFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christopher J. Kirk files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →